{"id":1345,"date":"2024-06-06T11:55:40","date_gmt":"2024-06-06T11:55:40","guid":{"rendered":"https:\/\/novaptech.com\/?page_id=1345"},"modified":"2025-02-11T14:15:54","modified_gmt":"2025-02-11T14:15:54","slug":"aptamers-as-therapeutics","status":"publish","type":"page","link":"https:\/\/novaptech.com\/en\/portfolio_page\/aptamers-as-therapeutics\/","title":{"rendered":"Aptamers as therapeutics"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Aptamers as therapeutics<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Aptamers have a huge potential as therapeutic agents. They can be addressed to intracellular targets, to membrane components or to circulating molecules. They can be used as drug-delivery agents to cells of interest. They can be employed as antagonists (preventing a specific receptor-ligand interaction), or as agonists (binding to a receptor and activating a signal). Aptamers can be easily modified for improving their properties (making them more resistant to nucleases or increasing their in vivo half-life). They induce a minimal immune response in vivo. Several clinical trials are on-going.<\/p>

Novaptech contributes to this field; see for instance :\u00a0<\/span><\/p>

Millozzi, F., Mil\u00e1n-Rois, P., Sett, A., Delli Carpini, G., De Bardi, M., Gisbert-Garzar\u00e1n, M., Sandon\u00e0, M., Rodr\u00edguez-D\u00edaz, C., Mart\u00ednez-Mingo, M., Pardo, I., Esposito, F., Viscomi, M. T., Bouch\u00e9, M., Parolini, O., Saccone, V., Toulm\u00e9, J.-J., Somoza, \u00c1., & Palacios, D. (2025). Aptamer-conjugated gold nanoparticles enable oligonucleotide delivery into muscle stem cells to promote regeneration of dystrophic muscles.<\/strong> <\/a>Nature Communications<\/em>, 16<\/strong>, Article 577.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Aptamers as therapeutics Aptamers have a huge potential as therapeutic agents. They can be addressed to intracellular targets, to membrane components or to circulating molecules. They can be used as drug-delivery agents to cells of interest. They can be employed as antagonists (preventing a specific receptor-ligand interaction), or as agonists (binding to a receptor and activating a signal). Aptamers can be easily modified for improving their properties (making them more resistant to nucleases or increasing their in vivo half-life). They induce a minimal immune response in vivo. Several clinical trials are on-going. Novaptech contributes to this field; see for instance :\u00a0 Millozzi, F., Mil\u00e1n-Rois, P., Sett, A., Delli Carpini, G., De Bardi, M., Gisbert-Garzar\u00e1n, M., Sandon\u00e0, M., Rodr\u00edguez-D\u00edaz, C., Mart\u00ednez-Mingo, M., Pardo, I., Esposito, F., Viscomi, M. T., Bouch\u00e9, M., Parolini, O., Saccone, V., Toulm\u00e9, J.-J., Somoza, \u00c1., & Palacios, D. (2025). Aptamer-conjugated gold nanoparticles enable oligonucleotide delivery into muscle stem cells to promote regeneration of dystrophic muscles. Nature Communications, 16, Article 577.<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":1339,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"footnotes":""},"class_list":["post-1345","page","type-page","status-publish","hentry"],"yoast_head":"\nAptamers as therapeutics - Novaptech<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/novaptech.com\/en\/portfolio_page\/aptamers-as-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aptamers as therapeutics - Novaptech\" \/>\n<meta property=\"og:description\" content=\"Aptamers as therapeutics Aptamers have a huge potential as therapeutic agents. They can be addressed to intracellular targets, to membrane components or to circulating molecules. They can be used as drug-delivery agents to cells of interest. They can be employed as antagonists (preventing a specific receptor-ligand interaction), or as agonists (binding to a receptor and activating a signal). Aptamers can be easily modified for improving their properties (making them more resistant to nucleases or increasing their in vivo half-life). They induce a minimal immune response in vivo. Several clinical trials are on-going. Novaptech contributes to this field; see for instance :\u00a0 Millozzi, F., Mil\u00e1n-Rois, P., Sett, A., Delli Carpini, G., De Bardi, M., Gisbert-Garzar\u00e1n, M., Sandon\u00e0, M., Rodr\u00edguez-D\u00edaz, C., Mart\u00ednez-Mingo, M., Pardo, I., Esposito, F., Viscomi, M. T., Bouch\u00e9, M., Parolini, O., Saccone, V., Toulm\u00e9, J.-J., Somoza, \u00c1., & Palacios, D. (2025). Aptamer-conjugated gold nanoparticles enable oligonucleotide delivery into muscle stem cells to promote regeneration of dystrophic muscles. Nature Communications, 16, Article 577.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/novaptech.com\/en\/portfolio_page\/aptamers-as-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Novaptech\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-11T14:15:54+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/novaptech.com\/portfolio_page\/aptamers-as-therapeutics\/\",\"url\":\"https:\/\/novaptech.com\/portfolio_page\/aptamers-as-therapeutics\/\",\"name\":\"Aptamers as therapeutics - Novaptech\",\"isPartOf\":{\"@id\":\"https:\/\/novaptech.com\/en\/#website\"},\"datePublished\":\"2024-06-06T11:55:40+00:00\",\"dateModified\":\"2025-02-11T14:15:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/novaptech.com\/portfolio_page\/aptamers-as-therapeutics\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/novaptech.com\/portfolio_page\/aptamers-as-therapeutics\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/novaptech.com\/portfolio_page\/aptamers-as-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/novaptech.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Portfolio page\",\"item\":\"https:\/\/novaptech.com\/portfolio_page\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Aptamers as therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/novaptech.com\/en\/#website\",\"url\":\"https:\/\/novaptech.com\/en\/\",\"name\":\"Novaptech\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/novaptech.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/novaptech.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/novaptech.com\/en\/#organization\",\"name\":\"Novaptech\",\"url\":\"https:\/\/novaptech.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/novaptech.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/novaptech.com\/wp-content\/uploads\/2024\/06\/cropped-LOGO.png\",\"contentUrl\":\"https:\/\/novaptech.com\/wp-content\/uploads\/2024\/06\/cropped-LOGO.png\",\"width\":335,\"height\":140,\"caption\":\"Novaptech\"},\"image\":{\"@id\":\"https:\/\/novaptech.com\/en\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aptamers as therapeutics - Novaptech","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/novaptech.com\/en\/portfolio_page\/aptamers-as-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"Aptamers as therapeutics - Novaptech","og_description":"Aptamers as therapeutics Aptamers have a huge potential as therapeutic agents. They can be addressed to intracellular targets, to membrane components or to circulating molecules. They can be used as drug-delivery agents to cells of interest. They can be employed as antagonists (preventing a specific receptor-ligand interaction), or as agonists (binding to a receptor and activating a signal). Aptamers can be easily modified for improving their properties (making them more resistant to nucleases or increasing their in vivo half-life). They induce a minimal immune response in vivo. Several clinical trials are on-going. Novaptech contributes to this field; see for instance :\u00a0 Millozzi, F., Mil\u00e1n-Rois, P., Sett, A., Delli Carpini, G., De Bardi, M., Gisbert-Garzar\u00e1n, M., Sandon\u00e0, M., Rodr\u00edguez-D\u00edaz, C., Mart\u00ednez-Mingo, M., Pardo, I., Esposito, F., Viscomi, M. T., Bouch\u00e9, M., Parolini, O., Saccone, V., Toulm\u00e9, J.-J., Somoza, \u00c1., & Palacios, D. (2025). Aptamer-conjugated gold nanoparticles enable oligonucleotide delivery into muscle stem cells to promote regeneration of dystrophic muscles. Nature Communications, 16, Article 577.","og_url":"https:\/\/novaptech.com\/en\/portfolio_page\/aptamers-as-therapeutics\/","og_site_name":"Novaptech","article_modified_time":"2025-02-11T14:15:54+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/novaptech.com\/portfolio_page\/aptamers-as-therapeutics\/","url":"https:\/\/novaptech.com\/portfolio_page\/aptamers-as-therapeutics\/","name":"Aptamers as therapeutics - Novaptech","isPartOf":{"@id":"https:\/\/novaptech.com\/en\/#website"},"datePublished":"2024-06-06T11:55:40+00:00","dateModified":"2025-02-11T14:15:54+00:00","breadcrumb":{"@id":"https:\/\/novaptech.com\/portfolio_page\/aptamers-as-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/novaptech.com\/portfolio_page\/aptamers-as-therapeutics\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/novaptech.com\/portfolio_page\/aptamers-as-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/novaptech.com\/en\/"},{"@type":"ListItem","position":2,"name":"Portfolio page","item":"https:\/\/novaptech.com\/portfolio_page\/"},{"@type":"ListItem","position":3,"name":"Aptamers as therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/novaptech.com\/en\/#website","url":"https:\/\/novaptech.com\/en\/","name":"Novaptech","description":"","publisher":{"@id":"https:\/\/novaptech.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/novaptech.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/novaptech.com\/en\/#organization","name":"Novaptech","url":"https:\/\/novaptech.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/novaptech.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/novaptech.com\/wp-content\/uploads\/2024\/06\/cropped-LOGO.png","contentUrl":"https:\/\/novaptech.com\/wp-content\/uploads\/2024\/06\/cropped-LOGO.png","width":335,"height":140,"caption":"Novaptech"},"image":{"@id":"https:\/\/novaptech.com\/en\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/novaptech.com\/en\/wp-json\/wp\/v2\/pages\/1345","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/novaptech.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/novaptech.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/novaptech.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/novaptech.com\/en\/wp-json\/wp\/v2\/comments?post=1345"}],"version-history":[{"count":16,"href":"https:\/\/novaptech.com\/en\/wp-json\/wp\/v2\/pages\/1345\/revisions"}],"predecessor-version":[{"id":3431,"href":"https:\/\/novaptech.com\/en\/wp-json\/wp\/v2\/pages\/1345\/revisions\/3431"}],"up":[{"embeddable":true,"href":"https:\/\/novaptech.com\/en\/wp-json\/wp\/v2\/pages\/1339"}],"wp:attachment":[{"href":"https:\/\/novaptech.com\/en\/wp-json\/wp\/v2\/media?parent=1345"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}